Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ami Pharm Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, SCHMIDT, IZABELA MARIA, and is located in 1 distinct art unit. SCHMIDT, IZABELA MARIA is the busiest examiner for the company, with 1 busiest examiner pending action. This 1 to 1 ratio between pending actions and examiners indicates that the company's current prosecution is focused on a single case. The 1 pending office action represents the full extent of the company's active engagement with the patent office in this sector.
Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution strategy is entirely dependent on the interactions with SCHMIDT, IZABELA MARIA. The busiest examiner pending count of 1 confirms that no other examiners are currently reviewing work for Ami Pharm Co. Ltd. This concentration simplifies the management of the portfolio, as there are no competing examiner perspectives to reconcile. Practitioners should prioritize understanding the specific preferences of SCHMIDT, IZABELA MARIA within the context of the 1 art unit involved. The 1 pending office action serves as the sole focus of the company's current patent efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18896502 | COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA AND SIDE EFFECTS AND METHOD OF ADMINISTRATION THEREOF | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18896502 | COMPOSITION FOR LOCALIZED FAT REDUCTION WITHOUT PAIN, EDEMA AND SIDE EFFECTS AND METHOD OF ADMINISTRATION THEREOF | SCHMIDT, IZABELA MARIA | 1621 | §103DP | Non-Final OA | — | Pending | Sep 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmi Pharm Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Izabela Maria Schmidt has the most, with 1 of Ami Pharm Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
